Research Article

MiR-766-3p Suppresses Malignant Behaviors and Stimulates Apoptosis of Colon Cancer Cells via Targeting TGFBI

Jianchao Gao,1 Lexue Fei,2 Xiaotang Wu,3 and Hua Li1

1Department of Gastrointestinal Surgery, TangShan Central Hospital, 063000 Tangshan, China
2Department of General Surgery, The Second Hospital of Tangshan, 063000 Tangshan, China
3Shanghai Engineering Research Center of Pharmaceutical Translation, 200231 Shanghai, China

Correspondence should be addressed to Hua Li; liauaaa@126.com

Received 18 August 2021; Revised 20 December 2021; Accepted 23 December 2021; Published 17 January 2022

Academic Editor: Antonio Giovanni Solimando

Copyright © 2022 Jianchao Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. MicroRNAs (miRNAs) can affect the progression of colon cancer cells. A variety of miRNAs, especially miR-766-3p, are proved to be abnormally expressed in colon cancer, but the molecular mechanism of miR-766-3p in this cancer has not yet been fully defined. Methods. Differentially expressed genes in the TCGA-COAD dataset were searched through bioinformatics analysis. MiR-766-3p and TGFBI mRNA levels were measured by qRT-PCR. TGFBI protein expression was measured via Western blot. Targeting relation between miR-766-3p and TGFBI was investigated by dual-luciferase reporter gene assay. Cell proliferation, invasion migration, and apoptosis were detected by cell functional assays. Results. MiR-766-3p was less expressed, while TGFBI was conspicuously highly expressed in colon cancer. MiR-766-3p high expression suppressed cell malignant behaviors and induced cell apoptosis in colon cancer. MiR-766-3p had targeting relation with TGFBI verified by dual-luciferase assay. The cancer-suppressive impact of miR-766-3p overexpression was attenuated by overexpressing TGFBI. Conclusions. MiR-766-3p/TGFBI axis suppressed malignant behaviors and facilitated apoptosis of colon cancer cells. MiR-766-3p may be an underlying target for colon cancer.

1. Introduction

Colon cancer is the third most frequent cancer throughout the world, with more than 1,800,000 new cases and 881,000 deaths in 2018, accounting for approximately 1/10 of all cancer cases and deaths [1]. It has been found by epidemiological, clinical, pathological, and molecular genetic studies that most colon cancers originate from adenomas. One or more simultaneous adenomas are usually found in surgical specimens of colon cancer, and risk of colon cancer elevates pronouncedly with the increased number of adenomatous polyps [2]. Patients’ cure rate is low since they are usually diagnosed at an advanced stage [3]. Although the treatment and diagnosis technologies of colon cancer are being constantly improved, nearly half of the patients have recurrence and metastasis [4]. Hence, to know the mechanism of colon cancer cells is vital for developing new diagnostic and therapeutic techniques.

MicroRNAs (miRNAs) can modulate expression of target genes by binding to the 3′-untranslated region (3′-UTR) of their mRNAs directly [5]. Abnormal miRNA expression may affect the pathogenesis of cancer [6–8]. The regulatory mechanisms of various miRNAs in colon cancer have been revealed in recent years. For instance, miR-378 is underexpressed in colon cancer, and miR-378 overexpression weakens proliferation and facilitates apoptosis of colon cancer cells [9]. MiR-137/TCF4 axis inhibits cell malignant behaviors in colon cancer [10]. The miR-144 restrains the growth of colon cancer by modulating SMAD4 [11]. Nevertheless, functions of miR-766-3p in colon cancer cells have not been studied yet.

TGFBI participates in various physiological processes, including differentiation, tumor progression, and metastasis [12]. Many reports have substantiated that TGFBI exerts a key role in cancer progression. TGFBI accelerates oral squamous cell carcinoma cell proliferation and is related to
the dismal prognosis of patients [13]. TGFβI overexpression facilitates the proliferative and migrative abilities of glioma cells [14]. However, no consensus has been reached on whether and under what circumstances TGFβI functions as a pro-oncogenic or antioncogenic molecule. For instance, TGFβI can work as a tumor inhibitor or promoter in ovarian cancer [15]. TGFβI mRNA level is higher in colon cancer tissues than in noncancer tissues [16]. Secretion of TGFβI in colon cancer cells has association with cancer invasiveness and extravasation [17].

Herein, we detected the miR-766-3p level in colon cancer and explored the effects of miR-766-3p on tumor cell behaviors in colon cancer through functional experiments. Then, the downstream target of miR-766-3p was screened out. The present study confirmed that miR-766-3p targeted TGFBI to modulate malignant progression of colon cancer cells.

2. Materials and Methods

2.1. Bioinformatics Approaches. Expression profiles of mature miRNAs (normal, 8; tumor, 450) and mRNAs (normal, 41; tumor, 473) of colon cancer along with corresponding clinical information were obtained from TCGA (https://portal.gdc.cancer.gov/). Differential analysis was done by utilizing "EdgeR" package to acquire differentially expressed mRNAs (DEmRNAs) and miRNAs (DEmiRNAs) (thresholds: |logFC| > 2 and padj < 0.05). MiR-766-3p (the target miRNA) was identified by literature consultation. The target mRNAs of miR-766-3p were analyzed by mirDIP (http://ophid.utoronto.ca/mirDIP/index_confirm.jsp), miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php), and TargetScan (http://www.targetscan.org/vert_72/) databases. The predicted results were then overlapped with the DEmRNAs to obtain the target DEmRNAs. Finally, correlation analysis was utilized to identify the target mRNA.

2.2. Cell Culture. Normal colon epithelial cell line FHC (BNCC281458) and 4 colon cancer cell lines SW480 (BNCC337664), HCT116 (BNCC353646), Caco-2 (BNCC350772), and SW620 (BNCC100162) were from BeNa Culture Collection (BNCC, China). SW620, SW480, and Caco-2 were incubated in the L15 medium (Gibco; Thermo Fisher Scientific, Inc., USA), while HCT116 and FHC cells were placed in DMEM (Nacalai Tesque, Japan). Both the mediums contained 1% penicillin-streptomycin (Sigma, MO, USA) as well as 10% fetal bovine serum (FBS). The culture environment was 37°C and 5% CO₂.

2.3. Cell Transfection. MiR-766-3p-mimic (miR-mimic) and control NC-mimic were from RioBio (Guangzhou, China). The pcDNA3.1-TGFBI vector (oe-TGFBI) was constructed by GenePharma (Shanghai, China), with empty vector pcDNA3.1 (oe-NC) as a negative control. Lipofectamine 2000 reagent (Invitrogen, Shanghai, China) was adopted for transfecting cells.

2.4. qRT-PCR. The mirVana miRNA Isolation Kit (Ambion, TX, USA) and TRIzol reagent (Invitrogen) were adopted for total RNA extraction. Then, reverse transcription of RNA was performed via the reverse transcription kit (Invitrogen) and miScript II RT kit. Real-time PCR was done using the SYBR® Premix Ex Taq™ II (Takara, Dalian, China) on the real-time PCR system (Bio-Rad Laboratories, CA, USA). The endogenous references were U6 and GAPDH. Table 1 lists the used primers.

2.5. Western Blot. Isolation of total proteins was completed by the RIPA lysis method. After treated by SDS-PAGE, samples were transferred onto the PVDF membrane (MilliporeSigma). Then, after blocked with 5% skim milk, the membrane was cultivated with the primary antibodies: rabbit anti-TGFBI (1:2000, ab170874, Abcam, China) and rabbit anti-GAPDH (1:10,000, ab181602, Abcam, China). Afterwards, incubation of the membrane and corresponding secondary antibody, goat anti-rabbit IgG H and L (HRP) (ab6721, Abcam, China) was carried out. Finally, the Odyssey Infrared Imaging System (Li-CorBiosciences, NE, USA) was implemented to visualized the protein bands.

2.6. CCK-8 Assay. CCK-8 assay (Dojindo, Kumamoto, Japan) was utilized for cell proliferation detection. Caco-2 cells were cultured in a 96-well plate for 12 h. Corresponding oligonucleotides or plasmids were utilized to transf ect cells. Then, CCK-8 solution was supplemented to the wells at the specified time points, followed by 1 h incubation at 37°C. Finally, the optical density (OD) value was detected at 450 nm.

2.7. Cell Invasion Assay. Transwell chamber (Millipore, USA) was implemented for cell invasion evaluation. First, the cells suspended in the L15 medium were added to the Matrigel-coated (BD, NJ, USA) upper compartment. The lower compartment was added with L15 containing 10% FBS. Then, cells failed to invade were removed after specified time. Meanwhile, the invading cells were handled with methanol for 10 min fixation and 0.1% crystal violet for 20 min staining. Cell count was performed under a light microscope.

2.8. Wound Healing Assay. Colon cancer cells were plated into a 12-well plate. After 24 h culture, the cell layer was scraped by a 10 μL pipette tip to form a wound. The cells were rinsed and then incubated in a medium without serum. At specified time points, the photos of wound were taken with an optical microscope. At last, ImageJ software (National Institutes of Health, MD, USA) was adopted to analyze the results.

2.9. Cell Apoptosis Assay. Cells (1 × 10⁵ cells/100 μL) were planted in a 6-well plate, treated twice with PBS 48 h following transfection, and then digested and resuspended by using 100 μL of binding buffer. Density of cells was adjusted
to 0.5 × 10^6 cells/100 μL. Next, Annexin V/FITC (5 μL) was used to stain the cells in darkness for 10 min. Subsequently, 100 μL of binding buffer was supplemented, and the plate was flicked to make the fluids mixed. Afterwards, cells staining was performed using 5 μL PI for 5 min in darkness. The blank control group was set up, and the same experimental steps were performed without staining. The apoptotic rate was detected within 1 h with FACSscan flow cytometry (BD Biosciences).

2.10. Dual-Luciferase Reporter Gene Detection. The mutant-type (MUT) or wild-type (WT) TGFBI mRNA 3′-UTR sequence was inserted into downstream of psiCHECK vectors (Sangon Co., LTD, China). Then, miR-766-3p-mimic/NC-mimic and TGFBI-WT/TGFBI-MUT were transfected into colon cancer Caco-2 cells. Cells were harvested 48 h following transfection, and luciferase activity was analyzed by the Luc-Pair™ Duo-Luciferase Assay Kit (GeneCopoeia, China).

2.11. Statistical Analysis. Data processing was performed with GraphPad Prism 6.0 (La Jolla, CA). All data were presented as mean ± standard deviation. Data comparison was done by Student’s t-test. P < 0.05 indicated a statistically remarkable difference.

3. Results

3.1. MiR-766-3p Is Lowly Expressed in Colon Cancer. Through differential analysis, 326 DEmiRNAs were obtained (Figure 1(a)). It is found through a literature review that miR-766-3p is less expressed and plays a pivotal part in various cancer tissues. Besides, expression analysis in TCGA indicated remarkable low level of miR-766-3p in colon cancer tissues (Figure 1(b)). Afterwards, result of qRT-PCR analysis uncovered that miR-766-3p was prominently less expressed in colon cancer cell lines (Figure 1(c)). It was suggested that miR-766-3p was downexpressed in colon cancer and may be a tumor inhibitor in cancer. Caco-2 with the lowest miR-766-3p level was utilized for the follow-up assays.

3.2. Forced Expression of MiR-766-3p Affects Cell Proliferation, Migration, Invasion, and Apoptosis in Colon Cancer. MiR-766-3p was overexpressed in Caco-2 cell line to study the effect of miR-766-3p on cell malignant behaviors in colon cancer. qRT-PCR result displayed that miR-766-3p expression was conspicuously high in the miR-mimic group (Figure 2(a)). CCK-8 result clarified that proliferation of colon cancer cells was weakened with overexpressed miR-766-3p (Figure 2(b)). The findings of transwell and wound healing assays denoted that miR-766-3p overexpression restrained cell invasion and migration in colon cancer (Figures 2(c) and 2(d)). Apoptosis assay exhibited that miR-766-3p overexpression dramatically stimulated apoptosis of colon cancer cells (Figure 2(e)). Thus, forced expression of miR-766-3p hampered cell malignant behaviors and stimulated cell apoptosis in colon cancer.

3.3. MiR-766-3p Targets and Inhibits TGFBI Expression in Colon Cancer. 2069 DEMRNAs were obtained in total through differential analysis (Figure 3(a)). The mRNAs targeted by miR-766-3p were analyzed by mirDIP, miR-TarBase, and TargetScan databases and intersected with the 1166 upregulated DEMRNAs in the TCGA-COAD dataset. Finally, one target mRNA was obtained (Figure 3(b)). A negative correlation between miR-766-3p and TGFBI was revealed by correlation analysis (Figure 3(c)). Besides, TGFBI was notably highly expressed in colon cancer tissues in TCGA (Figure 3(d)). Afterwards, we predicted the binding sites between the two and discovered that they had a binding site (Figure 3(e)). Next, dual-luciferase assay result suggested that highly expressed miR-766-3p remarkably suppressed the luciferase activity of TGFBI-WT, whereas that of TGFBI-MUT did not change (Figure 3(f)). MiR-766-3p overexpression dramatically restrained the TGFBI mRNA level in colon cancer cells, as measured by qRT-PCR (Figure 3(g)). Western blot also exhibited that the TGFBI protein level was pronouncedly reduced by overexpressed miR-766-3p (Figure 3(h)). The above conclusions signified that miR-766-3p repressed TGFBI expression in colon cancer cells.

3.4. MiR-766-3p Hampers Cell Malignant Behaviors and Accelerates Cell Apoptosis in Colon Cancer by Modulating TGFBI. To authenticate the impacts of miR-766-3p and TGFBI on colon cancer cells, we constructed a cell line with miR-766-3p overexpression (miR-mimic + oe-NC) and a cells line with simultaneous overexpression of TGFBI and miR-766-3p (miR-mimic + oe-TGFBI). According to the qRT-PCR result, TGFBI was dramatically lowly expressed in the miR-mimic + oe-NC group, while simultaneous

| Gene | Primer sequences (5′—3′) |
|------|-------------------------|
| MiR-766-3p | F: 5′-ACTCCAGCCCCACAGC-3′ |
|          | R: 5′-GTGCTATCCAGTGCAAGGTCCGAGCTGGATACGAGCTGAGCC-3′ |
| U6     | F: 5′-GTGCTGCTGCTCGGACG-3′ |
|          | R: 5′-GTGCTATCCAGTGCAAGGTCCGAGCTGGATACGACAAATATGGAAC-3′ |
| TGFBI  | F: 5′-GTGCGGCTAAATCTCTCCA-3′ |
|          | R: 5′-AAGCCCTGAAAACGCTGAT-3′ |
| GAPDH  | F: 5′-CGAGCCACATCGCTAGACA-3′ |
|          | R: 5′-GTGTTGAAGACGCCAGTGGA-3′ |

Table 1: Information of primer sequences.
Figure 1: MiR-766-3p is less expressed in colon cancer cells. (a) Volcano map of DEmiRNAs in the TCGA database (red dots, prominently upregulated DEmiRNAs, and green dots, significantly downregulated DEmiRNAs). (b) Box plot of the miR-766-3p level in TCGA (green box, normal, and red box, tumor). (c) MiR-766-3p level in the normal colon epithelial cell line FHC and colon cancer cell lines SW480, SW620, Caco-2, and HCT116. *P < 0.05.

Figure 2: Forced expression of miR-766-3p affects cell malignant behaviors and apoptosis in colon cancer. (a) MiR-766-3p transfection efficiency in Caco-2 cells. (b) The proliferative ability of Caco-2 cells. (c) Invasive ability of Caco-2 cells (100×). (d) Migratory ability of Caco-2 cells (40×). (e) Apoptotic rate of Caco-2 cells. *P < 0.05.
overexpression of TGFBI and miR-766-3p recovered the TGFBI expression level (Figure 4(a)). It was illustrated that miR-766-3p had a suppressive effect on the expression of TGFBI. (®_heresult of CCK-8 demonstrated that when miR-766-3p was overexpressed, the proliferative ability of colon cancer cells was outstandingly reduced, while this inhibitory effect was attenuated by concurrently overexpressing TGFBI and miR-766-3p (Figure 4(b)). (®_he results of cell invasion and wound healing assays indicated that miR-766-3p upregulation appreciably restrained cell migration and invasion of colon cancer cells, while such effect was weakened by simultaneously upregulating miR-766-3p and TGFBI (Figures 4(c) and 4(d)). Flow cytometry result clarified that overexpression of miR-766-3p markedly promoted cell apoptosis in colon cancer, while the upregulatory effect was suppressed by concurrently overexpressing miR-766-3p and TGFBI (Figure 4(e)). The above results proved that miR-766-3p hampered cell malignant phenotypes and accelerated cell apoptosis in colon cancer by downregulating TGFBI expression.

4. Discussion

The progression of colon cancer can be affected by onco-genes activation or the inactivation of antioncogenes [9]. The expression dysregulation of miRNA is closely linked with cancer progression [18]. Studies denoted that various miRNAs are differentially expressed in colon cancer. For instance, downexpressed miR-195 and miR-483 in colon cancer inhibit cancer cell proliferation and metastasis [19,20]. But how miR-766-3p functions in colon cancer remains to be investigated. Here, expression data of miRNAs in tumor tissues were downloaded from the TCGA-COAD dataset and analyzed through bioinformatics analysis, and
**Figure 4:** MiR-766-3p hampers cell malignant behaviors and stimulates cell apoptosis in colon cancer by downregulating TGFBI. (a) TGFBI mRNA expression in colon cancer cells Caco-2 (miR-NC + oe-NC, miR-mimic + oe-NC, and miR-mimic + oe-TGFBI). (b) Proliferation of Caco-2 cells. (c) Invasion of Caco-2 cells (100×). (d) Migration of Caco-2 cells (40×). (e) Apoptosis level of Caco-2 cells. *P < 0.05.
miR-766-3p expression in tumor cells was tested via qRT-PCR. Based on the results, miR-766-3p was less expressed in colon cancer, and it was speculated that miR-766-3p might be an inhibitor in colon cancer. The role of specific miRNAs in a certain cancer primarily depends on the gene expression in cancer [21]. Various assays have confirmed that the function of miR-766 differs in different cancer types. MiR-766 targets SOX6 to promote cell proliferation in colorectal cancer [22]. However, miR-766 can also induce p53 accumulation and G2/M arrest via modulating MDM4, which reduces cell proliferation in breast cancer [23]. MiR-766-3p is one of the miR-766 family members. You et al. [24] discovered that miR-766-3p/Wnt3a hampers liver cancer progression, but research of its specific role in other cancers is insufficient. A set of biological assays in this study authenticated that miR-766-3p upregulation inhibited cell malignant phenotypes and facilitated cell apoptosis in colon cancer, suggesting that miR-766-3p showed an inhibitory effect on colon cancer cells.

Through a conjoint analysis with related bioinformatics databases, we found that there was an interaction between miR-766-3p and TGFBI and that their expression was negatively correlated in colon cancer tissues. The dual-luciferase assay verified the targeting between miR-766-3p and TGFBI. TGFBI is also known as β3 integrin or keratoepithelin [25]. TGFBI participates in the progression of tumors [26], and its expression is elevated in esophageal squamous cell carcinoma [27], gastric cancer [28], and bladder cancer [29]. However, reduced TGFBI expression has been observed in some malignancies, such as breast cancer and lung cancer [30, 31] compared with normal tissues. Thus, the function of TGFBI seems to greatly rely on the cellular background. In this study, TCGA analysis exhibited that TGFBI was dramatically overexpressed in colon cancer tissues. Consistent with our results, TGFBI plays a tumor-promoting role in CRC, and silencing TGFBI inhibits in vivo tumor growth and in vitro angiogenesis [32]. Studies have substantiated that TGFBI has a targeting relation with some miRNAs. For instance, Yan et al. [33] discovered that miR-21-5p/TGFBI induces nonsmall cell lung cancer cell proliferation. Bissey et al. [34] found a targeting association between miR-449b and TGFBI. Our experiments proposed that miR-766-3p and TGFBI had a targeting relation in colon cancer cells. The effect of simultaneous abnormal expression of miR-766-3p and TGFBI on the malignant phenotypes and apoptosis of colon cancer cells was studied to explore the regulatory relationship and the functional mechanism of miR-766-3p and TGFBI in colon cancer. The results certified that overexpression of TGFBI hindered the inhibitory impact of miR-766-3p forced expression on cell malignant behaviors and the promotive effect on cell apoptosis in colon cancer. The above results pointed out that miR-766-3p hampered cell malignant behaviors and promoted apoptosis in colon cancer through targeting TGFBI.

Viewed in total, miR-766-3p was less expressed in colon cancer cells. Functional assays in vitro denoted that miR-766-3p hindered cell malignant behaviors and stimulated cell apoptosis in colon cancer. The oncogene TGFBI was considered to target by miR-766-3p and was involved in colon cancer progression induced by miR-766-3p. These results concluded that miR-766-3p may be a new biomarker for colon cancer.

Data Availability
The data and materials used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Jianchao Gao and Lexue Fei contributed equally. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Supplementary Materials
The protein bands of GAPDH and TGFβ1. (Supplementary Materials)

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] M. S. Cappell, “Pathophysiology, clinical presentation, and management of colon cancer,” Gastroenterology Clinics of North America, vol. 37, no. 1, pp. 1–24, 2008.
[3] H. Kim, Y. Yu, S. Choi et al., “Evodiamine eliminates colon cancer stem cells via suppressing notch and WNT signaling,” Molecules, vol. 24, no. 24, p. 4520, 2019.
[4] E. Van Cutsem, B. Nordlinger, A. Cervantes, and E. G. W. Group, “Advanced colorectal cancer: ESMO clinical practice guidelines for treatment,” Annals of Oncology, vol. 21, no. 5, pp. v93–v97, 2010.
[5] F. Xiao, S. Xiao, and M. Xue, “miR-139 controls viability of ovarian cancer cells through apoptosis induction and exosome shedding inhibition by targeting ATP7A,” OncoTargets and Therapy, vol. 12, pp. 10727–10737, 2019.
[6] A.-H. Wang, C.-H. Jin, G.-Y. Cui et al., “MIR210HG promotes cell proliferation and invasion by regulating miR-503-5p/TRAF4 axis in cervical cancer,” Aging, vol. 12, no. 4, pp. 3205–3217, 2020.
[7] S. Wang, G. Zhang, W. Zheng et al., “MiR-454-3p and MiR-374b-5p suppress migration and invasion of bladder cancer cells through targeting ZEB2,” Bioscience Reports, vol. 38, no. 6, 2018.
[8] D. Zhu, L. Gu, Z. Li, W. Jin, Q. Lu, and T. Ren, “MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2,” Pathology, Research & Practice, vol. 215, no. 5, pp. 861–872, 2019.
[9] M. Zeng, L. Zhu, L. Li, and C. Kang, “miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by...
inhibiting SDAD1,” *Cellular and Molecular Biology Letters*, vol. 22, no. 1, p. 12, 2017.

[10] W. P. Bi, M. Xia, and X. J. Wang, “miR-137 suppresses proliferation, migration and invasion of colon cancer cell lines by targeting TCF4,” *Oncology Letters*, vol. 15, pp. 8744–8748, 2018.

[11] S. Sheng, L. Xie, Y. Wu, M. Ding, T. Zhang, and X. Wang, “mir-144 inhibits growth and metastasis in colon cancer by down-regulating SMAD4,” *Bioscience Reports*, vol. 39, no. 3, 2019.

[12] K. Lang, S. Kahveci, N. Bonberg et al., “TGFBI protein is increased in the urine of patients with high-grade urothelial carcinomas, and promotes cell proliferation and migration,” *International Journal of Molecular Sciences*, vol. 20, no. 18, p. 4483, 2019.

[13] B.-J. Wang, K.-P. Chi, R.-L. Shen et al., “TGFBI promotes tumor growth and is associated with poor prognosis in oral squamous cell carcinoma,” *Journal of Cancer*, vol. 10, no. 20, pp. 4902–4912, 2019.

[14] S.-K. Guo, M.-F. Shen, H.-W. Yao, and Y.-S. Liu, “Enhanced expression of TGFBI promotes the proliferation and migration of glioma cells,” *Cellular Physiology and Biochemistry*, vol. 49, no. 3, pp. 1138–1150, 2018.

[15] M. P. Ween, M. K. Oehler, and C. Ricciardelli, “Transforming growth factor-beta-induced protein (TGFBI)/βig-H3): a matrix protein with dual functions in ovarian cancer,” *International Journal of Molecular Sciences*, vol. 13, no. 8, pp. 10461–10477, 2012.

[16] P. Buckhaults, C. Rago, B. St Croix et al., “Secreted and cell surface genes expressed in benign and malignant colorectal tumors,” *Cancer Research*, vol. 61, pp. 6996–7001, 2001.

[17] C. Ma, Y. Rong, D. R. Radloff et al., “Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation.” *Genes & Development*, vol. 22, no. 3, pp. 308–321, 2008.

[18] S. Mishra, T. Yadav, and V. Rani, “Exploring miRNA based approaches in cancer diagnostics and therapeutics,” *Critical Reviews in Oncology*, vol. 98, pp. 12–23, 2016.

[19] B. Li, S. Wang, and S. Wang, “MiR-195 suppresses colon cancer proliferation and metastasis by targeting WNT3A,” *Molecular Genetics and Genomics*, vol. 293, no. 5, pp. 1245–1253, 2018.

[20] Z.-Y. Niu, W.-L. Li, D.-L. Jiang, Y.-S. Li, and X.-J. Xie, “MiR-483 inhibits colon cancer cell proliferation and migration by targeting TRAF1,” *The Kaohsiung Journal of Medical Sciences*, vol. 34, no. 9, pp. 479–486, 2018.

[21] C. Yang, X. Ma, G. Guan et al., “MicroRNA-766 promotes cancer progression by targeting NR3C2 in hepatocellular carcinoma,” *The FASEB Journal*, vol. 33, no. 1, pp. 1456–1467, 2019.

[22] C.-F. Li, Y.-C. Li, L.-B. Chen et al., “MicroRNA-766 targeting regulation of SOX6 expression promoted cell proliferation of human colorectal cancer,” *OncoTargets and Therapy*, vol. 8, pp. 2981–2988, 2015.

[23] C. Chen, S. Xue, J. Zhang et al., “DNA-methylation-mediated repression of miR-766-3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma,” *International Journal of Cancer*, vol. 141, no. 9, pp. 1867–1878, 2017.

[24] Y. You, K. Que, Y. Zhou et al., “MicroRNA-766-3p inhibits tumour progression by targeting Wnt3a in hepatocellular carcinoma,” *Molecules and Cells*, vol. 41, pp. 830–841, 2018.

[25] J.-E. Kim, S.-J. Kim, B.-H. Lee, R.-W. Park, K.-S. Kim, and I.-S. Kim, “Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-β-induced gene, βig-h3,” *Journal of Biological Chemistry*, vol. 275, no. 40, pp. 39097–39095, 2000.

[26] Y. Zhang, G. Wen, G. Shao et al., “TGFBI deficiency predisposes mice to spontaneous tumor development,” *Cancer Research*, vol. 69, no. 1, pp. 37–44, 2009.

[27] D. Otsawa, T. Yokobori, M. Sohda et al., “TGFBI expression in cancer stromal cells is associated with poor prognosis and hematogenous recurrence in esophageal squamous cell carcinoma,” *Annals of Surgical Oncology*, vol. 23, no. 1, pp. 282–289, 2016.

[28] B. Han, H. Cai, Y. Chen et al., “The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis,” *Molecular Cancer*, vol. 14, no. 1, pp. 64, 2015.

[29] J. Zou, R. Huang, H. Li et al., “Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells,” *Cancer Management and Research*, vol. 11, pp. 6995–7006, 2019.

[30] G. Calaf, C. Echiburú-Chau, Y. Zhao, and T. Hei, “BigH3 protein expression as a marker for breast cancer,” *International Journal of Molecular Medicine*, vol. 21, pp. 561–568, 2008.

[31] Y. Zhao, M. El-Gabry, and T. K. Hei, “Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells,” *Molecular Carcinogenesis*, vol. 45, no. 2, pp. 84–92, 2006.

[32] B. Chiavarina, B. Costanza, R. Ronca et al., “Metastatic colorectal cancer cells maintain the TGFβ program and use TGFβ to fuel angiogenesis,” *Theranostics*, vol. 11, no. 4, pp. 1626–1640, 2021.

[33] L. Yan, J. Ma, Y. Wang et al., “miR-21-5p induces cell proliferation by targeting TGFBI in non-small cell lung cancer cells,” *Experimental and Therapeutic Medicine*, vol. 16, pp. 4655–4663, 2018.

[34] P.-A. Bissey, J. H. Law, J. P. Bruce et al., “Dysregulation of the MiR-449b target TGFβ alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma,” *Onco genesis*, vol. 7, no. 5, p. 40, 2018.